Summary.-The blastogenic response to a crude cell extract of ovarian cancer cells has been studied in 48 patients with ovarian cancer (9, autologous, 39 allogeneic), in 26 female controls matched for age and in 18 female patients with other types of cancer in remission from disease. The responses in ovarian cancer patients in remission and relapse were considered separately. The blastogenic responses to cell extracts of foetal ovary, foetal lung, foetal liver and normal adult ovary were also assessed in a proportion of all 3 groups.
AN IMMUNE response which appears to be directed towards tumour antigens has been demonstrated in vitro for several human tissues (Hellstrom et al., 1971) . Attention in recent years has been centred on the cell mediated immune response to tumours and this response appears to be instrumental in facilitating tumour rejection (Burnet, 1968) .
Cultured peripheral lymphocytes will transform into lymphoblasts when challenged in vitro by an antigen to which the host has previously been sensitized (Coulson and Chalmers, 1967; Bouveng, Gardwell and Low, 1967) . We have determined whether the lymphocytes from patients with ovarian cancer will transform when challenged with ovarian cancer cell extracts and whether there is any correlation between the extent of disease and the ability of the lymphocytes to transform in vitro.
Much attention has been given to embryonic antigens in recent years and the hypothesis that " tumour specific antigens " are re-expressed embryonic ahtigens has been derived from studies on viral and chemically induced animal tumours (Coggin, Ambrose and Anderson, 1970; Coggin et al., 1971; Baldwin, Glaves and Vose, 1972) . We have therefore also looked at the blastogenic response to a cell extract of foetal ovary to see whether an oncofoetal antigen might be at least partly responsible for this blastogenic response.
To assess whether the blastogenic responses were in any way caused by normal ovarian constituents in the tumour or foetal extracts, lymphocytes from patients in all 3 groups were challenged with cell extracts from normal ovarian tissue.
MATERIALS AND METHODS
Tumour and normal ovarian cell extracts (CE) were obtained by a modified method AbbreviatiorLs: FCS, Foetal Calf Serum; AS, Autologous Serum; CE, Cell Extract, ct/min.; S.I. Stimulation Index (S.I. = Stimulated ct/min/Unstimulated ct/min).
described by Oren and Herberman (1971) . Approximately 5 g of fresh tumour was disaggregated in 0 14 mol/I sodium chloride (1 ml/g wet tissue) by high speed homogenization, frozen rapidly in liquid nitrogen and then thawed; finally hypotonic saline was added. The tumour suspension was centrifuged at 400 q (4°C) after each of these procedures, the supernatant fluid from each stage being pooled and centrifuged at 105,000 g at 4°C for one hour. The protein content of the resultant supernatant was estimated by the technique of Lowry, Rosebrough and Farr (1952) .
Preparation of the foetal tissue extracts was modified slightly. The initial stage was as described above but in the final stage the extract was centrifuged at 3000 g at 4°C for one hour and the resulting supernatant used to assess blastogenic responses; this modification was introduced to procure a larger yield of protein than would have resulted from iiltracentrifugation.
Lymphocytes were prepared by layering defibrinated blood over Ficoll/Triosil (B0yum, 1968) and subsequently resuspending in Tissue Culture Medium 199 containing 12 * 5% of autologous or foetal calf serum, at a concentration of 106 lymphocytes/ml. Then 100 jg of the ovarian cancer, normal ovary or foetal ovary cell extract (CE) was added to appropriate tubes containing 1 x 106 lymphocytes, the amount of CE for optimal blastogenesis being determined by doseresponse assay. Each experiment was performed in duplicate.
The lymphocyte cultures were incubated for 5 days at 37°C in 5% C02, pulsed with 1 0 UCi 1251 UDR (5 iodo-2 deoxyuridine) for 4 h and harvested by washing twice with Hanks' medium and once with 10% cold trichloracetic acid. The 125J UDR incorporation into the acid insoluble fraction was then measured by using a Wilj gamma counter.
Lymphocyte responses in 48 patients with ovarian cancer, 18 females with other cancers in remission from disease and 26 controls were challenged with CE from serous papillary cystadenocarcinoma of the ovary. The controls were normal nonpregnant females aged between 32 and 74 years, mostly awaiting elective surgery for prolapse.
Eighteen of the patients with ovarian cancer, 13 with other cancers and 13 controls were tested for responses to foetal ovary; in these patients blastogenic responses to foetal liver or lung (from the same foetus) were also assessed to evaluate the possibility of transplantation allo-antigenic responses.
Responses to normal ovarian extracts were assessed in 11 of the ovarian cancer patients, 7 normal controls and 8 patients with other cancers, to determine whether any responses to ovarian cancer or ovarian foetal extracts could be attributed to sensitization to normal tissue determinants.
No patients had had any chemotherapy or radiotherapy for at least 2 months before these tests were performed, and none of the allogeneic tests were conducted on patients who had received a blood transfusion for at least 6 months before the test was carried out.
RESULTS

Dose response assays for ovarian cancer cell extract (CE)
1 X 106 lymphocytes were stimulated with doses of CE varying between 50 and 200 /tg wherever this was possible (Fig. 1) .
From the data obtained we calculated that the optimal dose for blastogenic stimulation was generally 100 ,ug.
Blastogenic responses
The blastogenic responses to 100 Hg CE for patients with ovarian cancer both in remission and relapse and for patients with other cancers are shown in Fig. 2 (Khoo and Mackay, 1974) . In vitro lymphocyte impairment has been demonstrated in non-lymphoid tumours by Catalona, Sample and Chretien (1973) . However, Di Saia et al. (1971) when the lymphocytes were incubated in group, and the fact that transformation FCS. to autologous CE occurred in 6 of 11 In experiments where allogeneic CE patients, suggests that HLA does not was used, histocompatibility (HLA) anti-contribute to the blastogenic response in gen could have induced transformation, this system. This is consistent with the but the fact that there was no significant findings of Mavligit et at. (1973) The tendency for lymphocytes from patients with endometrioid ovarian cancer to transform when challenged with CE of serous papillary carcinoma requires further consideration. If the response is due to a tumour specific antigen this would suggest that the antigen is possibly organ-specific and this could include sensitization to normal ovarian determinants.
The ovarian tumours dealt with in this paper share a common embryological origin and the possibility that an oncofoetal antigen was responsible for the organ specific responses therefore prompted us to investigate this aspect further. This idea has been substantiated to some extent by the blastogenic response to ovarian foetal ovary extract and has not hitherto been reported. From our data, the response to foetal ovary appears to be tumour associated, although the responses are greater in the ovarian cancer patients.
In view of the fact that we have also demonstrated blastogenic responses to normal ovarian cell extract, the existence of ovarian cancer oncofoetal antigens should be regarded with some reserve until determinants in normal adult ovary responsible for blastogenesis can be excluded from a purified extract of foetal ovary.
A cell mediated response to normal breast tissue has been demonstrated in patients with breast cancer (Alford, Hollinshead and Herberman, 1973) and to normal lung tissue in patients with lung cancer (Hollinshead, Stewart and Herberman, 1974 ). It appears that the same holds true for ovarian cancer patients in their response to normal ovary extracts. This would fit in with the postulate that exposure to normal cell constituents by a break down of the basement membrane in tumours can sensitize the cancer patients to these normal cell products (Hall, 1974) . Antigens which could be responsible for the blastogenic effect of normal ovarian extract include normal tissue antigen described by Dickinson et al. (1974) and oncofoetal antigens which may occur in normal tissue (Burtin, 1974) . More sophisticated methods are required to detect an autoimmune element in the host response to tumour and we are investigating this possibility further.
Conclusion
Patients with ovarian cancer in remission have a blastogenic response to autologous and allogeneic ovarian cancer cell extract which is significantly greater than in control patients. The response is reduced in relapse patients. This implies sensitization to a determinant (s) in the extract which is not demonstrable in relapse; incubating the lymphocytes in FCS only marginally improves the response. Although the major response has been in patients with ovarian cancer, it does not appear to be specific to these tumours. Our work suggests that there are determinants which are shared by ovarian tumours of different histology but of the same postulated embryological origin; since we have demonstrated a blastogenic response to foetal ovary extract, these shared antigens may be oncofoetal. Nevertheless, because we have also demonstrated blastogenic responses to normal ovary, it will be necessary to eliminate the determinants responsible for this before the exact nature of any " tumour associated" antigen can be established. 
